Effect of the Addition of Netarsudil 0.02% vs. Brimonidine 0.1% in Normal Tension Glaucoma Patients Currently on Latanoprost 0.005%
A randomized, multicenter, investigator-masked prospective study of NTG patients currently on latanoprost 0.005% monotherapy, to study the effect of IOP change with the introduction of netarsudil 0.02% vs brimonidine 0.1%. Subjects will be assessed at a screening visit, and 1 follow-up visit. Clinical evaluations will include visual acuity and IOP .
• Patients 18 years and older
• Diagnosed with normal tension glaucoma based on the following:
‣ IOP ≤ 21mmHg
⁃ Optic nerve rim thinning and/or retinal nerve fiber layer (RNFL) loss consistent with glaucoma
⁃ Normal visual field OR visual field loss consistent with optic nerve or RNFL defects within the last year
⁃ Open angles assessed by gonioscopy
• Have been on latanoprost monotherapy for at least 6 weeks